-

Agilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC Speed

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent 1290 Infinity III Fluorescence Detector (FLD), a new fluorescence detector designed specifically for modern ultra-high-performance liquid chromatography (UHPLC) workflows. The detector extends fluorescence detection into the UHPLC era by combining ultra-trace sensitivity, UHPLC-ready chromatographic performance, and routine-ready ease of use.

Designed for use as a standalone detector or in-line with LC/MS systems, the 1290 Infinity III FLD helps laboratories gain more analytical evidence and greater confidence from every injection. The detector preserves narrow UHPLC peak integrity while delivering rich spectral information, supporting confident decision-making in trace-level analysis.

“The 1290 Infinity III Fluorescence Detector is designed to deliver clear customer value by combining ultra-trace sensitivity, UHPLC-ready peak integrity, and richer analytical insight in one workflow,” said Iris Mangelschots, vice president and general manager of the Liquid Phase Division at Agilent. “As laboratories increasingly adopt UHPLC-driven workflows to improve throughput, reduce cost per sample, and accelerate return on investment, this detector provides a differentiated solution that strengthens analytical confidence while helping customers get more value from their systems, methods, and samples.”

As UHPLC adoption continues to grow, laboratories face increasing pressure to achieve higher confidence at trace levels without sacrificing speed, data quality, or scalability. Traditional fluorescence detectors were not designed for the narrow peaks and fast separations typical of UHPLC methods. The 1290 Infinity III FLD addresses this gap through a design optimized for modern UHPLC workflows.

By delivering high sensitivity while preserving chromatographic performance, the detector supports faster method development and easier interpretation of complex samples. When used in-line with LC/MS, it adds orthogonal fluorescence detection to complement mass spectrometric data, providing additional analytical evidence without increasing workflow complexity.

The 1290 Infinity III FLD is designed to add value across a wide range of applications, including biopharmaceutical analysis, food safety testing, and environmental monitoring. Its combination of performance and usability supports laboratories as they scale methods from development into robust, routine operation while maintaining confidence in results.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact
Kate Coyle
Agilent Technologies Inc.
+1 302-633-7490
kate.coyle@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact
Kate Coyle
Agilent Technologies Inc.
+1 302-633-7490
kate.coyle@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Announces Cash Dividend of 26.25 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 26.25 cents per share of common stock. The quarterly dividend will be paid on January 27, 2027, to all shareholders of record as of the close of business on January 5, 2027. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in anal...

Agilent to Participate in 9th Annual Evercore Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in the upcoming 9th Annual Evercore Healthcare Conference. Agilent management is scheduled to participate in a fireside chat from 10 a.m. to 10:50 a.m. EST on Tuesday, Dec. 1, 2026, in Coral Gables, Florida. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Technologies Agilent Technologies Inc...

Agilent Expands Tumor Profiling Portfolio with SureSelect Cancer Research Pan Heme

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the SureSelect Cancer Research Pan Heme, a hybrid capture-based next-generation sequencing (NGS) research solution for comprehensive genomic profiling of hematologic malignancies. Developed in collaboration with experts at Roswell Park Comprehensive Cancer Center, the solution integrates DNA and RNA profiling, automated sample preparation and bioinformatics in a streamlined workflow. The introduction of Su...
Back to Newsroom